Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Winder Laboratories, LLC
EIR
•Winder Laboratories, LLC•March 13, 2020

Winder Laboratories, LLC – FDA EIR, Mar 13, 2020

Record Details

An FDA inspection of Winder Laboratories, LLC, conducted from March 9-13, 2020, identified significant deficiencies in the company's quality control systems and adherence to current Good Manufacturing Practices (cGMP), referencing 21 CFR Part 211. Major violations included a failure to adequately test the purified water system for objectionable microorganisms and total yeast and mold counts (TYMC), as required by 21 CFR 211.84(d)(6). Management exhibited a lack of awareness regarding these essential testing requirements and the identification of objectionable organisms. The company also demonstrated a widespread failure to thoroughly investigate unexplained discrepancies, out-of-specification (OOS), and out-of-trend (OOT) results for water quality, as mandated by 21 CFR 211.192. These investigations were often incomplete, lacking organism identification and sufficient evidence, even while products were manufactured using compromised water. Furthermore, the inspection identified inadequate handling of customer complaints, per 21 CFR 211.198(b)(3). Complaint records frequently lacked documentation of investigation decisions, thoroughness, and timely follow-up, extending to incomplete batch record reviews and broader product impact assessments. Other issues included deficient water system and equipment cleaning validations, untimely annual product reviews, and a failure to attach raw data to investigations. Required actions include implementing comprehensive microbial testing for the water system, conducting robust investigations into all quality deviations, ensuring timely and thorough complaint handling, and improving validation protocols and documentation to comply with regulatory standards. Management acknowledged these issues and indicated plans to engage consultants and update procedures.

Company
Winder Laboratories, LLC
Inspection date
March 13, 2020
Product type
drugs
Office
Division of Pharmaceutical Quality Operations II
Person
  • Susan O. Oladeji
View Company Profile

ID · 243c080e-839a-421c-93b5-50ac4ac240cf

Violation Codes1
21 CFR 211.84(d)(6)

Full citation text and observation details available on the Dashboard.

Other documents for Winder Laboratories, LLC
  • 483 - 2026-02-03February 3, 2026
  • 483 - 2025-08-05August 5, 2025
  • WARNING_LETTER - 2025-08-05August 5, 2025
  • 483 - 2023-02-03February 3, 2023
  • 483 - 2020-03-13March 13, 2020

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Winder Laboratories, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.